Kieran T. Gallahue is Chairman of the Intersect ENT Board of Directors and member of the Board’s Audit Committee.  He served as named Executive Chairman of the Board of Directors from May 2019 to May 2020 and as Interim President and CEO from June 2019 through July 2019. Kieran has more than 20 years of strategic, operational and corporate management experience in the healthcare industry, with deep expertise in the medical technologies field. He previously served as Chairman and CEO at CareFusion from 2011 until March 2015, and prior to that, he was President, CEO and a Director of ResMed.  Kieran serves as a member of the board of directors of Envista Holdings, a dental technology company, Edwards Lifesciences (NYSE: EW), a global leader in the science of heart valves and hemodynamic monitoring, and Arena Pharmaceuticals (NASDAQ: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas.  He holds a bachelor’s degree in economics from Rutgers University and a master’s degree from Harvard Business School.

Tom West was named Chief Executive Officer and a member of the Board of Directors in July 2019. Previously, he served as Division President, Diagnostics Solutions at Hologic, Inc. At Hologic, he delivered consistent, above-market revenue growth rates in the domestic and international diagnostics business, achieving over $1.1 billion in worldwide diagnostics sales and reversing previous declines. Prior to Hologic, Tom held various roles of increasing responsibility at Johnson & Johnson, including serving as Worldwide Vice President of Strategy and Business Development for Johnson & Johnson’s Diabetes Solutions Companies. He also served as President of LifeScan North America and as President of LifeScan EMEA. Tom earned a Bachelor’s degree in politics and economics from Princeton University and a Master of Business Administration from the Wharton School at the University of Pennsylvania.

Terri Kline Teresa Kline joined the Intersect ENT board of directors in August 2017. Terri is a leader in health care insurance, managed care, physician practice management, and outpatient facility management. Most recently, Terri was President and CEO of Health Alliance Plan (HAP), a Michigan-based nonprofit health plan providing coverage to nearly 700,000 members, where she provided strategic, financial, and operational leadership for the organization and its five subsidiaries. She was also an Executive Vice President of Henry Ford Health System, which is comprised of hospitals, medical centers and one of the nation's largest group practices, the Henry Ford Medical Group. Previously, Terri served as Senior Vice President and Chief Healthcare Management Officer for Health Care Service Corporation (HCSC), Senior Vice President of HealthSouth, CEO of United Healthcare of Georgia, and Regional Vice President of Aetna Health Plans. She also serves on the board of directors of Presbyterian Health Plan in New Mexico and on the board of directors at Amadisys, Inc., headquartered in Baton Rouge, LA.  Terri holds a bachelor’s degree in biology from Kalamazoo College and a master of public health degree from the University of Michigan.

Cynthia Lucchese joined Intersect ENT’s board of directors in July 2014.  Cindy is Chief Administrative Officer and CFO of Hulman & Company in Indianapolis, Ind. She has over three decades of financial management experience in the healthcare industry and has held CFO positions at two publicly traded companies, Hillenbrand, Inc. (formerly Batesville Holdings, Inc.), and Thoratec Corp.  She had also held several positions at Guidant including Corporate Vice President and Treasurer. Cindy currently serves on the board of directors at Hanger Orthopedics (NYSE: HNGR) and previously served on the board of directors of Brightpoint, Inc. from 2009 to 2012. A Certified Public Accountant, Cindy received a B.S. with distinction in Accounting and an M.B.A. in Finance from the Indiana University Kelley School of Business.

Dana G. Mead, Jr. joined Intersect ENT’s board of directors in June 2007. Since May 2019, Dana has served as President and CEO of HeartFlow, a cardiovascular diagnostics company. Previously Dana served as President and CEO of BVI Medical, Inc., a medical device company in ophthalmology. He spent 10 years as a partner at Kleiner Perkins Caufield & Byers (KPCB) supporting innovative entrepreneurial startup companies in the firm’s life sciences practice. Before joining KPCB, Dana served in a variety of leadership roles at Guidant, including President of Vascular Intervention. He currently serves on the board of directors of Inspire Medical Systems (NYSE: INSP) and previously served on the Board of Directors at telehealth platform company Teladoc, Inc. (TDOC), California Healthcare Institute, Lucile Packard Children’s Hospital at Stanford University, and the Cardiovascular Research Foundation, along with several other private innovative medical device start-ups. Dana received his B.A. from Lafayette College and holds an M.B.A. from the University of Southern California.

Frederic H. Moll, M.D.joined Intersect ENT’s board of directors in March 2006. Dr. Moll founded and led Auris Health through its acquisition by Ethicon, a Johnson & Johnson company, in April 2019, and now serves as the Chief Development Officer of Johnson & Johnson. Widely recognized as a leader in robotic surgery and medical technology innovation, Dr. Moll played a founding role at a number of companies including Intuitive Surgical, Restoration Robotics, Hansen Medical, Origin Medsystems and Endotherapeutics. Since 2011, Dr. Moll has also served on the Board of Directors of Shockwave Medical (NASDAQ: SWAV), a medical device company and previously served on the Board of Directors of several other public companies including Biolase, Hansen Medical, and MAKO Surgical.  Dr. Moll holds a B.A. from the University of California, Berkeley, an M.S. from Stanford University and an M.D. from the University of Washington School of Medicine.

Anthony Vernon joined Intersect ENT’s board of directors in April 2015. Tony served as CEO of Kraft Foods Group, Inc. from 2012 to 2014, and as President of Kraft Foods North America and Executive Vice President of the former parent of Kraft Foods Group, Inc. from 2009 to 2012, and was a member of the board of directors of Kraft Foods Group, Inc. until May 2015. Prior to joining Kraft, Tony was the healthcare industry partner of Ripplewood Holdings LLC, a private equity firm. He held a variety of leadership positions during a 23-year career at Johnson & Johnson, where he led a number of the company’s largest franchises. Tony currently also serves on the board of directors of NovoCure (NASDAQ: NVCR) and McCormick & Company, Incorporated (NYSE: MKC). He previously served as a Director of Uluru, Inc. (NASDAQ: ULUR) and MediVation (acquired). Anthony holds a bachelor's degree from Lawrence University and a M.B.A. from the Kellogg Graduate School of Management at Northwestern University.